News

SL-701 is designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that occur in both adults and children. Antitumor activity

The announcement also includes the study in Liberia sponsored by investigators at the University of Oxford and the supportive Phase II trial of brincidofovir for Ebola Virus Disease

Vyvanse is the first and only medication approved for sale in the US for the treatment of this disorder. The approval was based on results from two randomized,

The CRISPR genome-editing tool helps scientists to make changes in specific genes and it has two components, including a homing device to a specific section of DNA (guide-RNA)

MOXIe (A two-part, randomized, placebo-controlled Phase 2/3 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich’s Ataxia) is a multi-center study in

The patent, along with the company’s existing intellectual property, demonstrates VG Life Sciences’ expertise in researching the role of CLIP (class II-associated invariant chain peptide) in chronic inflammatory

PREZCOBIX is a once-daily, fixed-dose antiretroviral combination tablet containing 800 mg of darunavir, marketed as PREZISTA in the United States, and 150 mg of cobicistat, a pharmacokinetic enhancer

This indication constitutes a population of patients with a serious and life-threatening condition reflected by a higher risk of progression to cirrhosis and liver failure. OCA is currently

The patent will expire no earlier than July 2032. The allowed claims cover a compound, pharmaceutical composition and method of treating certain cell proliferation diseases, including solid tumors,